Integrative analysis identifies STX16 as a prognostic and immune-associated biomarker in ccRCC
Open Access
- 20 November 2025
- journal article
- research article
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 41094
Abstract
STX16 has been studied in various cancers, where it is suggested to regulate tumor cell proliferation, migration, and invasion by affecting vesicle trafficking and signal transduction pathways. However, its specific role in clear cell renal cell carcinoma (ccRCC) remains unclear. This study aims to systematically investigate the expression patterns, clinical significance, prognostic value and functional role of STX16 in ccRCC. Bioinformatics analyses using TCGA, CTPAC, TIMER, and UALCAN databases evaluated STX16 expression, clinical correlations, prognosis, and immune infiltration. Functional enrichment, co-expression, and PPI analyses explored STX16-associated pathways. Single-cell sequencing elucidated tumor microenvironment heterogeneity. Laboratory validation included Western blot, immunohistochemistry, and functional assays with siRNA-mediated STX16 knockdown in ccRCC cell lines. STX16 was significantly upregulated at mRNA and protein levels in ccRCC tissues. High STX16 expression correlated with advanced tumor stages, poor overall survival (OS), and disease-specific survival (DSS). Multivariable Cox regression identified STX16 as an independent prognostic factor. STX16 influenced immune infiltration, particularly involving CD4 + T cells, macrophages, and neutrophils, and was associated with immune pathways. Single-cell sequencing revealed heterogeneous STX16 expression across tumor microenvironment cell types. STX16 knockdown inhibited proliferation, migration, and invasion of ccRCC cell lines. STX16 is upregulated in ccRCC and acts as an independent prognostic factor associated with poor outcomes. Its role in promoting tumor progression and modulating immune infiltration highlights STX16 as a potential biomarker and therapeutic target in ccRCC.Keywords
Funding Information
- Beijing Municipal Administration of Hospitals’ Ascent Plan (DFL20190502)
- Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX201820)
- National Natural Science Foundation of China (81801429)
This publication has 39 references indexed in Scilit:
- Myeloid effector cells in cancerCancer Cell, 2024
- Renal Cell CarcinomaJAMA, 2024
- Tumor-infiltrating regulatory T cells as targets of cancer immunotherapyCancer Cell, 2023
- Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR StudyEuropean Urology Oncology, 2023
- Associations of circulating mediators of inflammation, cell regulation and immune response with esophageal squamous cell carcinomaJournal of Cancer Research and Clinical Oncology, 2021
- Toward understanding the origin and evolution of cellular organismsProtein Science, 2019
- Biological Functions of Autophagy Genes: A Disease PerspectiveCell, 2019
- Macrosomia, obesity, and macrocephaly as first clinical presentation of PHP1b caused by STX16 deletionAmerican Journal of Medical Genetics Part A, 2016
- Spatiotemporal Dynamics of Intratumoral Immune Cells Reveal the Immune Landscape in Human CancerImmunity, 2013
- SNAREs and trafficBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2005